Evidence map›Paper›PMID 28645005›Full record

ArticleStem cell research2017

Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.

Claudia Wing, Masaaki Komatsu, Shannon M Delaney, Matthew Krause, Heather E Wheeler, M Eileen Dolan

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Claudia WingSection of Hematology/Oncology, Department of Medicine, Chicago, IL, USA.
Masaaki KomatsuSection of Hematology/Oncology, Department of Medicine, Chicago, IL, USA.
Shannon M DelaneySection of Hematology/Oncology, Department of Medicine, Chicago, IL, USA.
Matthew KrauseCommittee of Molecular Pathogenesis and Molecular Medicine, The University of Chicago, Chicago, IL, USA.
Heather E WheelerSection of Hematology/Oncology, Department of Medicine, Chicago, IL, USA.
M Eileen DolanSection of Hematology/Oncology, Department of Medicine, Chicago, IL, USA. Electronic address: edolan@medicine.bsd.uchicago.edu.
University of Chicago · US

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1M
Whole GenomeU01GM061393 · NIGMS · UNIVERSITY OF CHICAGO · PI RATAIN, MARK J · 2000 to 2014
$39.0M
Genetic Susceptibility and Biomarkers of Platinum-related ToxicitiesR01CA157823 · NCI · UNIVERSITY OF ROCHESTER · PI TRAVIS, LOIS B. · 2012 to 2025
$11.2M
Genetic determinants associated with pemetrexed response and toxicityR01CA136765 · NCI · UNIVERSITY OF CHICAGO · PI DOLAN, MARY EILEEN · 2009 to 2013
$1.6M
NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA136765NCI NIH HHS R01 CA157823NIGMS NIH HHS U01 GM061393
6 · The paper itself

Abstract

The generation of induced pluripotent stem cells (iPSCs) and differentiation to cells composing major organs has opened up the possibility for a new model system to study adverse toxicities associated with chemotherapy. Therefore, we used human iPSC-derived neurons to study peripheral neuropathy, one of the most common adverse effects of chemotherapy and cause for dose reduction. To determine the utility of these neurons in investigating the effects of neurotoxic chemotherapy, we measured morphological differences in neurite outgrowth, cell viability as determined by ATP levels and apoptosis through measures of caspase 3/7 activation following treatment with clinically relevant concentrations of platinating agents (cisplatin, oxaliplatin and carboplatin), taxanes (paclitaxel, docetaxel and nab-paclitaxel), a targeted proteasome inhibitor (bortezomib), an antiangiogenic compound (thalidomide), and 5-fluorouracil, a chemotherapeutic that does not cause neuropathy. We demonstrate differential sensitivity of neurons to mechanistically distinct classes of chemotherapeutics. We also show a dose-dependent reduction of electrical activity as measured by mean firing rate of the neurons following treatment with paclitaxel. We compared neurite outgrowth and cell viability of iPSC-derived cortical (iCell® Neurons) and peripheral (Peri.4U) neurons to cisplatin, paclitaxel and vincristine. Goshajinkigan, a Japanese herbal neuroprotectant medicine, was protective against paclitaxel-induced neurotoxicity but not oxaliplatin as measured by morphological phenotypes. Thus, we have demonstrated the utility of human iPSC-derived neurons as a useful model to distinguish drug class differences and for studies of a potential neuroprotectant for the prevention of chemotherapy-induced peripheral neuropathy.

Indexed as

Cell DifferentiationHumansInduced Pluripotent Stem CellsNeuronsPeripheral Nervous System DiseasesBortezomibGoshajinkiganIPSC-derived neuronsNeuropathyPlatinating agentsStem cellsTaxanesThalidomide

Identifiers

PMID28645005
PMCPMC5737666
OpenAlexW2626731085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.